Lower alpha fetoprotein and higher risk of hepatocellular carcinoma, study from the type 2 diabetes mellitus patients [0.03%]
糖尿病患者AFP减低与肝癌风险升高关系的研究
Shaoling Yang,Lu Liu,Yili Luo et al.
Shaoling Yang et al.
Aims: To explore the association of type 2 diabetes mellitus (T2DM) with hepatocellular carcinoma (HCC) and alpha fetoprotein (AFP). Methods: ...
Type 2 diabetes and influence of diabetes-specific distress on depression [0.03%]
2型糖尿病及其特异性心理压力对抑郁的影响
Mukut Roy,Nilanjan Sengupta,Pranab Kumar Sahana et al.
Mukut Roy et al.
Aims: Common psycho-social emotional reactions of patients with diabetes may be termed as diabetes-specific distress which is conceptually distinctive from depression. In patients with type 2 diabetes, different screening...
Visceral fat accumulation is associated with increased plasma sphingosine-1-phosphate levels in type 2 diabetes mellitus [0.03%]
2型糖尿病患者体内脂肪蓄积与血浆鞘氨醇-1-磷酸水平升高有关
Sayuri Tanaka,Ippei Kanazawa,Toshitsugu Sugimoto
Sayuri Tanaka
Objective: Accumulating evidence has shown that sphingosine-1-phosphate (S1P) plays roles in glucose and fat metabolism. However, the association between plasma S1P levels and fat mass, especially visceral fat mass, remai...
Time- and frequency-domain measures of heart rate variability predict cardiovascular outcome in patients with type 2 diabetes [0.03%]
二维和频域心率变异性指标可预测2型糖尿病患者的临床结局
Seon-Ah Cha,Yong-Moon Park,Jae-Seung Yun et al.
Seon-Ah Cha et al.
Aims: To evaluate the association between impaired heart rate variability (HRV) and cardiovascular disease (CVD) in patients with type 2 diabetes (T2DM). ...
Erratum to "Severe hypoglycemia in pregnant women with type 2 diabetes-A relevant clinical problem" [Diabetes Res. Clin. Pract. 102 (2013) e17-e18] [0.03%]
糖尿病孕妇严重低血糖的一个重要临床问题——一则病例的更正说明[糖尿病研究与临床实践杂志，2013，102卷，e17-e18页]
Anna L Secher,Elisabeth R Mathiesen,Henrik U Andersen et al.
Anna L Secher et al.
The association of self-efficacy and hospitalization rates in people with type-2 diabetes: A prospective cohort study [0.03%]
自我效能感与2型糖尿病患者住院率相关性的前瞻性队列研究
Haoyu Zhao,Jeffrey A Johnson,Fatima Al Sayah et al.
Haoyu Zhao et al.
Aims: Self-efficacy is presumed important in chronic disease management; we assessed the association between self-efficacy and risk of hospitalization in adults with type-2 diabetes. ...
Impact of treatment with glibenclamide or vildagliptin on glucose variability after aerobic exercise in type 2 diabetes: A randomized controlled trial [0.03%]
二甲双胍或维格列汀对2型糖尿病患者有氧运动后血糖波动的影响：一项随机对照试验
Aline Fofonka,Patrícia Martins Bock,Karina Rabello Casali et al.
Aline Fofonka et al.
Aims: To evaluate the glucose variability, oxidative stress, metabolic and cardiovascular responses after an aerobic exercise session in diabetic patients on treatment with metformin plus vildagliptin or glibenclamide. ...
Randomized Controlled Trial
Diabetes research and clinical practice. 2018 Sep:143:184-193. DOI:10.1016/j.diabres.2018.07.007 2018
Clinical usefulness of the body muscle-to-fat ratio for screening obstructive sleep apnea syndrome in patients with inadequately controlled type 2 diabetes mellitus [0.03%]
身体肌脂比筛查2型糖尿病患者阻塞性睡眠呼吸暂停综合征的临床价值
Noboru Kurinami,Seigo Sugiyama,Hiroko Ijima et al.
Noboru Kurinami et al.
Aims: To investigate whether body composition measures can be used for screening obstructive sleep apnea syndrome (OSAS) in patients with type 2 diabetes mellitus (T2DM) suspected of having OSAS. ...
The relationship between circulating adiponectin, ADIPOQ variants and incident cardiovascular disease in type 2 diabetes: The Fremantle Diabetes Study [0.03%]
2型糖尿病患者中循环脂联素、ADIPOQ基因多态性与心血管疾病发病的关系：弗里曼特尔糖尿病研究结果
Kirsten E Peters,Wendy A Davis,John Beilby et al.
Kirsten E Peters et al.
Aims: To investigate the relationship between serum adiponectin, ADIPOQ variants and haplotypes, and cardiovascular disease (CVD) in type 2 diabetes (T2D). ...
Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists [0.03%]
2型糖尿病心血管预后研究：SGLT2抑制剂与GLP-1受体激动剂的比较
André J Scheen
André J Scheen
Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are two pharmacological classes that have proven their efficacy to reduce major cardiovascular events (MACEs) in patients with...